BioSig unit picked for NVIDIA-backed Inception program for AI developers
Shutthiphong Chandaeng

BioSig Technologies (NASDAQ:BSGM) traded higher on Thursday after the medical device company announced that its subsidiary, BioSig AI Sciences, Inc., was selected to join the NVIDIA (NASDAQ:NVDA) Inception program for AI developers.
The program initiated by the chipmaker provides software and hardware support for AI startups, helping the participants during critical stages of product development. Partners to the program can also get access to the latest technology and connect with venture capitalists.

"We are thrilled to join an elite group of AI-centric technology companies leading the evolution of machine learning and AI across industries," CEO and Founder of BioSig (BSGM), Ken Londoner, said.
"We believe NVIDIA Inception will help advance BioSigâs role in identifying transformational applications of AI opportunities in healthcare, Londoner added.

BioSig's (BSGM) selection for NVDA Inception program marks the latest AI-related development in the healthcare space. Shares of Recursion Pharmaceuticals (RXRX) jumped last week after the biotech announced a $50 million investment from NVIDIA (NVDA), rallying its peers in the industry. 


More on BioSig

BioSig Technologies regains compliance with Nasdaq listing standards
BioSig names Steve Buhaly CFO replacing Chaussy